期刊
CANCERS
卷 12, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/cancers12102854
关键词
EphA2; ephrinA1-Fc; prostate cancer; breast cancer; cell migration; metastasis
类别
资金
- NIH [NS107479, CA168517, CA242620, CA233452]
- City of Hope/UCR (CUBRI) research grant
Simple Summary We demonstrate that pro-oncogenic EphA2 (ephrin type-A receptor 2) expression is activated in aggressive prostate cancers, and in mouse models of prostate cancers that are treated with enzalutamide. We also demonstrate in mouse models, that agonistic EphA2 targeting agents are very effective in suppressing cell migration and tumor metastases, hence anticipating the possible use of such agents in innovative anti-metastatic therapeutic modalities. The EphA2 tyrosine kinase receptor is highly expressed in several types of solid tumors. In our recent studies, we targeted EphA2 in pancreatic cancer with agonistic agents and demonstrated that suppression of EphA2 significantly reduced cancer-cell migration in cell-based assays. In the present study, we focused on targeting EphA2 in prostate cancer. While not all prostate cancers express EphA2, we showed that enzalutamide induced EphA2 expression in prostate cancer cells and in a patient-derived xenograft (PDX) animal model, which provides further impetus to target EphA2 in prostate cancer. Western blot studies showed that agonistic dimeric synthetic (135H12) and natural (ephrinA1-Fc) ligands effectively degraded EphA2 receptor in the prostate cancer cell line PC-3. The agents also delayed cell migration of prostate cancer (PC-3) cells, while an in vivo PC-3 orthotopic metastatic nude-mouse model also revealed that administration of ephrinA1-Fc or 135H12 strongly reduced metastases. The present study further validates EphA2 as an important target in metastatic prostate cancer treatment. Our results should incentivize further efforts aimed at developing potent and effective EphA2 synthetic agonistic agents for the treatment of EphA2-driven aggressive metastatic tumors including prostate, pancreatic, and breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据